Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis: A Real-Life Study
International Archives of Allergy and Immunology · 2024
DOI: 10.1159/000534902 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Archives of Allergy and Immunology, 2024. Verfasst von Francisco Javier Bravo-Gutiérrez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonology Department, University General Hospital Santa Lucía, Cartagena (Murcia), Spain. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Nasal Polyps, Asthma, Pulmonary Eosinophilia. Die Arbeit wurde bisher 7-mal zitiert (Crossref).
Abstract (Originalsprache)
Introduction
Asthma is one of the most common chronic diseases and affects around 334 million people worldwide. The estimated prevalence of severe asthma is 3–10% of the asthmatic population. Mepolizumab has demonstrated efficacy in reducing exacerbations, oral corticosteroid use, and improving quality of life, asthma control, and lung function in patients with severe eosinophilic asthma (SEA). Our study aimed to check the response to mepolizumab in a series of severe asthma patients regarding exacerbations, oral corticosteroid use, asthma control, quality of life, and lung function and to compare the response between patients with and without nasal polyps.
Method
This is a retrospective, multicenter study of RE-ASGRAMUR (Register of Severe Asthma of the Region of Murcia) performed in eight hospitals of the Region of Murcia (Spain) under routine clinical practice conditions. We included patients diagnosed with SEA who completed at least 1 year of treatment with mepolizumab. We analyzed clinical characteristics, drug tolerance, and effectiveness: exacerbations, ACT, miniAQLQ, forced expiratory volume in 1 s (FEV1), and use of oral corticosteroids. We also compared the results between patients with and without nasal polyps.
Results
The median of exacerbations before treatment was 3 and decreased to 0 after treatment (mean decrease of 77.4%). The median diary oral prednisone intake was 15 mg before treatment and 5 mg after treatment (mean 56% reduction). We have obtained a significant improvement in other variables: ED visits and hospitalizations, asthma control (ACT), quality of life (miniAQLQ), and lung function (FEV1). Thirty-four out of 70 patients (48.57%) fulfilled the criteria of super-responder, and 17 out of 70 (24.29%) had a complete response. More patients in the group with nasal polyps fulfilled the criteria of super-responder and complete response to mepolizumab.
Conclusions
Mepolizumab is a safe and effective treatment for SEA patients, improving exacerbations, oral corticosteroid intake, asthma control, quality of life, and lung function. In patients with associated nasal polyposis, there is a statistically significant higher proportion of super-responders and complete responders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmonology Department, University General Hospital Santa Lucía, Cartagena (Murcia), Spain.
- Allergy Department, University General Hospital Reina Sofia, Murcia, Spain.
- Paediatrics Department, University General Hospital Santa Lucia, Cartagena (Murcia), Spain.
- Pulmonology Department, University General Hospital Morales Meseguer, Murcia, Spain.
- Pulmonology Department, University Clinic Hospital Virgen de la Arrixaca, Murcia, Spain.
- Pulmonology Department, University General Hospital Los Arcos, San Javier (Murcia), Spain.
Zitieren
APA
Bravo-Gutiérrez, F. J., Miralles-López, J. C., Valverde-Molina, J., Alemany Francés, M. L., Andújar-Espinosa, R., Castilla-Martínez, M., Avilés-Inglés, M. J., Mora-González, A., Pajarón-Fernández, M. J., Cabrejos-Perotti, S., Meseguer-Arce, J., Flores Martín, I., Pérez-Fernández, V., & RE-ASGRAMUR Group (2024). Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis: A Real-Life Study. International Archives of Allergy and Immunology. https://doi.org/10.1159/000534902
Vancouver
Bravo-Gutiérrez FJ, Miralles-López JC, Valverde-Molina J, Alemany Francés ML, Andújar-Espinosa R, Castilla-Martínez M, et al. Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis: A Real-Life Study. International Archives of Allergy and Immunology. 2024. doi:10.1159/000534902
BibTeX
@article{BravoGutirrez2024,
author = {Bravo-Gutiérrez, Francisco Javier and Miralles-López, Juan Carlos and Valverde-Molina, José and Alemany Francés, María Loreto and Andújar-Espinosa, Rubén and Castilla-Martínez, Manuel and Avilés-Inglés, María Jesús and Mora-González, Ana and Pajarón-Fernández, Manuel José and Cabrejos-Perotti, Sheila and Meseguer-Arce, José and Flores Martín, Isabel and Pérez-Fernández, Virginia and RE-ASGRAMUR Group, RE-ASGRAMUR Group},
title = {Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis: A Real-Life Study},
journal = {International Archives of Allergy and Immunology},
year = {2024},
doi = {10.1159/000534902}
}
EUVIMED